
Novavax announced the development of a protein-based monovalent XBB COVID-19 vaccine with the intention of it being manufactured and available for the fall vaccination campaign.

Luke Halpern is an associate editor with Pharmacy Times. Luke wrote for Pharmacy Times in the summer of 2023 and assumed a full-time role in June 2024. His work has been featured in Pharmacy Times and the American Journal of Managed Care. He graduated from the University of Massachusetts, Amherst, in May 2024.

Novavax announced the development of a protein-based monovalent XBB COVID-19 vaccine with the intention of it being manufactured and available for the fall vaccination campaign.

Standard prediction models that assess an individual’s risk of developing dementia and how to prevent it are limited in their ability to do so, showing high error rates and a higher chance of receiving a false-positive result, according to a recent study.

A single dose of axicabtagene ciloleucel in patients with large B-cell lymphoma led to significantly higher overall survival and progression-free survival rates, as well as improvements in quality of life and faster recovery in comparison to standard care therapy.

In-person visits to receive oral therapy, outpatient infusions, and inpatient infusion for the treatment of hematologic neoplasms declined in the early months of the COVID-19 pandemic, while telemedicine use increased slightly in the same period but remained low overall.

A single infusion of ciltacabtagene autoleucel produced a lower risk of death and disease progression, as well as deep and durable responses, in heavily pretreated patients with relapsed/refractory multiple myeloma.